INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///

NEWS

Filter By
  • 10/04/2023

    Stanford University

    Researchers from Tempus partnered with Stanford University to study the genomic landscape and immunotherapy biomarkers of metastatic renal cell carcinoma (RCC) patients with and without pancreatic metastases. Pancreatic metastases in RCC have been associated with features associated with worse response to immunotherapy. This study compared the genomic landscape and immunotherapy biomarkers of metastatic RCC patients with and without pancreatic metastases. The study found that RCC patients with pan...

  • 06/26/2023

    Roswell Park Comprehensive Cancer Center

    Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer.  FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions. This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023...

  • 06/08/2023

    UCLA Mattel Children’s Hospital

    Researchers from Tempus have partnered with the UCLA Mattel Children's Hospital to expand the TIME Trial Program and help pediatric patients access clinical trials. With the addition of UCLA, TIME will expand trial access to pediatric and adolescent/young adult (AYA) patients for the first time. Dr. Noah Federman, the Nancy and Jonat...

  • 04/19/2023

    Northwestern University, Baylor University, Cedar Sinai & University of Pittsburgh

    Researchers from Tempus studied the mutational landscape of patients with metastatic breast cancer. Partners in the study included: Northwestern University's Robert H. Lurie Comprehensive Cancer Center; Baylor University's Dan L. Duncan Comprehensive Cancer Center; Cedar Sinai’s Samuel Oschin Comprehensive Cancer Center; and University of Pittsburgh’s Hillman Cancer Center. CDK4/6 inhibitors (CDK4/6i), such as palbociclib, ribociclib, and abemaciclib, in combination with antiestro...

  • 04/03/2023

    University of California Irvine

    Researchers from Tempus partnered with University of California Irvine to study the immune biomarker environment and co-mutational landscape in TERT-mutated versus wild-type renal cell carcinoma.  This study conducted the largest analysis to date of the molecular and immune landscape of TERT-mutated renal cell carcinoma (RCC). The analysis revealed that traditional immune biomarkers such as TMB and PD-L1 were not highly prevalent in RCC compared to Urothelial Carcinoma (UC)...

  • 03/21/2023

    City of Hope

    Researchers from Tempus partnered with City of Hope to study the differences in tumor microenvironment and mutational landscape of primary and metastatic colorectal cancer sites. This study utilized the whole transcriptome expression data of liver metastasis and lung metastasis in microsatellite stable colorectal cancer. The results uncovered a significant finding: a more favorable immune profile was found in lung metastasis compared to liver metastasis. This discovery has the potential to revolutioniz...

  • 01/11/2023

    University of California Los Angeles

    Researchers from Tempus partnered with the University of California Los Angeles to study the genomic landscape of small cell lung cancer (SCLC) in never smoking patients. The first and largest analysis of a rare subgroup (3-7%) of SCLC patients with no smoking history. Lung cancer in never smokers is a high unmet need due to its rising incidence over the past 20+ years. Historically, most SCLC clinical trials have e...

  • 12/07/2022

    MD Anderson Cancer Center & Dana–Farber Cancer Institute

    Researchers from Tempus partnered with MD Anderson Cancer Center and the Dana-Farber Cancer Institute to study the value of germline testing in patients with advanced cancer.  Recent studies have found that 12-17% of cancer patients carry pathogenic germline variants (genetic alterations) that translate to cancer predisposition. Despite this, many cancer patients do not meet guidelines for testing and these germline pathogenic variants go undetect...

  • image description

    Ayala Pharmaceuticals

    As part of a larger collaboration, Ayala Pharmaceuticals has chosen Tempus as the preferred sequencing partner to support in screening and recruiting patients for its TENACITY AL101 study, a therapy targeting triple negative breast cancer. The collaboration aims to identify patients with various NOTCH alterations to accurately match and enroll them into the TENACITY trial operating in the U.S., Euro...